Logo image
Back
Cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries: a systematic review
Journal article   Open access   Peer reviewed

Cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries: a systematic review

Afsana Afroz, Mohammed J. Alramadan, Md Nassif Hossain, Lorena Romero, Khurshid Alam, Dianna J. Magliano and Baki Billah
BMC health services research, Vol.18(1), pp.972-972
2018
DOI: https://doi.org/10.1186/s12913-018-3772-8
PMCID: PMC6296053
PMID: 30558591
pdf
Published1.08 MBDownloadView
Published (Version of Record)CC BY V4.0,  Open Access

Abstract

Health Care Sciences & Services Life Sciences & Biomedicine Science & Technology
Background Diabetes is one of the world’s most prevalent and serious non-communicable diseases (NCDs). It is a leading cause of death, disability and financial loss; moreover, it is identified as a major threat to global development. The chronic nature of diabetes and its related complications make it a costly disease. Estimating the total cost of an illness is a useful aid to national and international health policy decision making. The aim of this systematic review is to summarise the impact of the cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries, and to identify methodological gaps in measuring the cost-of-illness of type 2 diabetes mellitus. Methods This systematic review considers studies that reported the cost-of-illness of type 2 diabetes in subjects aged 18 years and above in low and lower-middle income countries. The search engines MEDLINE, EMBASE, CINAHL, PSYCINFO and COCHRANE were used form date of their inception to September 2018. Two authors independently identified the eligible studies. Costs reported in the included studies were converted to US dollars in relation to the dates mentioned in the studies. Results The systematic search identified eight eligible studies conducted in low and lower-middle income countries. There was a considerable variation in the costs and method used in these studies. The annual average cost (both direct and indirect) per person for treating type 2 diabetes mellitus ranged from USD29.91 to USD237.38, direct costs ranged from USD106.53 to USD293.79, and indirect costs ranged from USD1.92 to USD73.4 per person per year. Hospitalization cost was the major contributor of direct costs followed by drug costs. Conclusion Type 2 diabetes mellitus imposes a considerable economic burden which most directly affects the patients in low and lower-middle income countries. There is enormous scope for adding research-based evidence that is methodologically sound to gain a more accurate estimation of cost and to facilitate comparison between studies.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

80 File views/ downloads
25 Record Views
87 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.26 Diabetes
1.26.42 Diabetes Management
Web Of Science research areas
Health Care Sciences & Services
ESI research areas
Clinical Medicine
Logo image